The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice

Vaccine

Volumn 24, Issue 44-46, 2006, Pages 6585-6587

  Cox, Rebecca Jane ^a   Hovden, Arnt Ove ^a   Brokstad, Karl Albert ^a,b   Szyszko, Ewa ^a   Madhun, Abdullah Sami ^a   Haaheim, Lars Reinhardt ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Immune response; Influenza vaccine; Mouse; Split virus vaccine; Whole virus vaccine

Indexed keywords

HEMAGGLUTININ; IMMUNOGLOBULIN G; INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY-PRODUCING CELLS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

EID: 33846369187     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.040     Document Type: Article

References (21)

1. Hehme N., Engelmann H., Kunzel W., Neumeier E., and Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 191 3-4 (2002) 203-208
2. Hehme N., Engelmann H., Kuenzel W., Neumeier E., and Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103 1-2 (2004) 163-171
3. Nicholson K.G., Colegate A.E., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 9272 (2001) 1937-1943
4. Stephenson I., Bugarini R., Nicholson K.G., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 1210-1215
5. Stephenson I., Nicholson K.G., Gluck R., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362 9400 (2003) 1959-1966
6. Hovden A.O., Cox R.J., and Haaheim L.R. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol 62 (2005) 36-44
7. Hovden A.O., Cox R.J., Madhun A., and Haaheim L.R. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol 62 4 (2005) 342-352
8. Keitel W.A., Couch R.B., Cate T.R., Hess K.R., Baxter B., Quarles J.M., et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 32 10 (1994) 2468-2473
9. Renegar K.B., Small Jr. P.A., Boykins L.G., and Wright P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173 3 (2004) 1978-1986
10. Renegar K.B., and Small Jr. P.A. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146 6 (1991) 1972-1978
11. Renegar K.B., and Small Jr. P.A. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J Virol 65 4 (1991) 2146-2148
12. Nicholson K.G. Human influenza. In: Nicholson K.G., Webster R.G., and Hay A.J. (Eds). Textbook of influenza (1998), Blackwell Science, Oxford 219-264
13. Murphy B.R., and Webster R.G. Orthomyxoviruses. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields virology. 3rd ed. (1996), Lippincott-Raven Publishers, Philadelphia 1397-1445
14. Kennedy R., Undale A.H., Kieper W.C., Block M.S., Pease L.R., and Celis E. Direct cross-priming by Th lymphocytes generates memory cytotoxic T cell responses. J Immunol 174 7 (2005) 3967-3977
15. Trombetta E.S., and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23 (2005) 975-1028
16. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., and Kida H. Intranasal immunisation with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21 23 (2003) 3212-3218
17. Arkema A., Huckriede A., Schoen P., Wilschut J., and Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 18 14 (2000) 1327-1333
18. Bungener L., Serre K., Bijl L., et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20 17-18 (2002) 2287-2295
19. Schumacher R., Adamina M., Zurbriggen R., et al. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 22 5-6 (2004) 714-723
20. Keitel W.A., Cate T.R., Nino D., et al. Immunisation against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis 183 2 (2001) 329-332
21. Szyszko, E, Brokstad, K, Cox, R J, Hovden, A.-O, Madhun, A, Haaheim, LR. Impact of influenza vaccine formulation with a detailed analysis of the cytokine profile. Scand J Immunol 2006; in press.